<DOC>
	<DOCNO>NCT01639040</DOCNO>
	<brief_summary>The purpose study assess safety REGN668 ( SAR231893 ) administer concomitantly topical corticosteroid ( TCS ) patient moderate-to-severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Study Assess Safety REGN668 ( SAR231893 ) Administered Concomitantly With Topical Corticosteroids ( TCS ) Patients With Moderate-to-severe Atopic Dermatitis ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Male female patient age 18 year old 2 . Chronic AD present least 2 year 1 . Prior treatment REGN668 ( SAR231893 ) 2 . Hypersensitivity corticosteroids ingredient contain TCS product use study 3 . AD lesion locate face , flexural , genital area 4 . Certain treatment medical procedure , undertaken within particular time frame prior baseline visit , preclude eligibility participation study 5 . Treatment live ( attenuate ) vaccine within 12 week baseline visit 6 . Treatment investigational drug within 8 week 7 . Known history human immunodeficiency virus ( HIV ) infection 8 . Presence certain laboratory abnormality screen visit 9 . History certain opportunistic infection certain clinical parasite infection 10 . History malignancy within 5 year baseline visit , certain exception 11 . Pregnant breastfeed woman 12 . Travel within 12 month study start area endemic parasitic infection , develop country Africa tropical subtropical region Asia 13 . History alcohol drug abuse within 2 year screen visit 14 . Any medical psychiatric condition , opinion investigator sponsor 's medical monitor , would place patient risk , interfere participation study , interfere interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>